Greg Chopiuk
Genomics Institute of the Novartis Research Foundation(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, PI3K/AKT/mTOR signaling in cancer, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited
- → Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK(2006)375 cited
- → (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors(2015)62 cited